Gene therapy represents a promising therapeutic option for many inherited and acquired retinal diseases. Recombinant adeno-associated viral vectors (AAV) are the most efficient tools to transfer genes in vivo to the retina. The recent identification of dozens of novel AAV serotypes enormously expands on the versatility of AAV as vector system for in vivo somatic gene transfer. The results from the forthcoming trials with AAV in the retina of patients with Leber Congenital Amaurosis will be critical for the rapid development of AAV-based therapeutics for retinal diseases.
Wild-type AAV and recombinant AAV vectors
Adeno-associated viruses (AAVs) belong to the Parvoviridae family. These non-human pathogens possess a linear, single-stranded DNA genome that can replicate in the presence of different helper viruses such as adenovirus, herpes virus or papilloma virus (Muzyczka, 2001) . AAVs were originally isolated as contaminants from laboratory stocks of adenoviruses.
The AAV genome (4.7 kb) consists of two open reading frames, rep, required for viral genome replication; and cap, encoding AAV structural proteins, rep and cap DNA sequences are enclosed within two symmetric T shaped palindromic terminal sequences called inverted terminal repeats (ITRs) (Muzyczka, 2001) . Recombinant vectors are generated by deleting the rep and cap sequences from the genome and by inserting the therapeutic gene of interest between the ITRs.
AAV vectors are particularly advantageous for gene transfer because of their ability to transduce non-dividing cells, and the possibility of a long and sustained levels of therapeutic gene expression. Since the generation of the first recombinant AAV2 vector (Hermonat & Muzyczka, 1984; Tratschin, West, Sandbank, & Carter, 1984) , 108 novel capsid sequences have been isolated (from 55 human and 53 non-human primates), and some of them were used to generate novel vectors for gene transfer (Chiorini, Kim, Yang, & Kotin, 1999; Chiorini, Yang, Liu, Safer, & Kotin, 1997; Gao et al., 2002; Gao et al., 2004; Gao, Vandenberghe, & Wilson, 2005; Rutledge, Halbert, & Russell, 1998; Xiao et al., 1999) . Recombinant vectors can be generated using both capsid proteins and genomes from the same serotype or the vector genome can be derived from AAV2, and included in the capsid from an alternative AAV serotype ( Fig. 1) (Chao et al., 2000; Hildinger et al., 2001) . This allows to assess the net contribution of the capsid proteins to vector transduction. Exchanging capsids among various AAV serotypes is effective for conferring specific cellular tropism and intensity as well as onset of gene expression (Fig. 1) . For example, AAV 2/1 (Gregorevic et al., 2004; , 2/7 , 2/8 (Wang et al., 2005) and 2/9 (Inagaki et al., 2006; Pacak et al., 2006) (where the first number defines the vector genome and the second the capsid) efficiently transduce muscle and heart by either direct or sys- temic vector administration. AAV2/8 and 2/9 are particularly amenable for liver-directed gene transfer Inagaki et al., 2006) , while AAV 2/1 (Burger et al., 2004; Passini et al., 2003) , 2/4 (Liu, Martins, Chiorini, & Davidson, 2005) , 2/5 (Burger et al., 2004; Mastakov, Baer, Kotin, & During, 2002) , 2/9 and Rh10 (Cearley & Wolfe, 2006) can transduce different cells of the central nervous system (CNS). In addition, AAV2/6 (Halbert, Allen, & Miller, 2001) , 2/5 Zabner et al., 2000) and 2/9 (Limberis & Wilson, 2006) efficiently transfer genes to conducting airway as well as alveolar cells. Onset of gene expression is also capsid dependent as vectors with AAV5 or 1 capsids have detectable levels of transgene expression within days following subretinal administration while AAV2/2 vectors require weeks to achieve the same levels of gene expression . The combination of specificity and efficiency of in vivo gene transfer derived from the use of the various AAV serotypes has allowed the development of novel therapeutic options for inherited and acquired human diseases.
Recombinant AAV vectors in the retina
The structure and accessibility of the retina makes it an ideal target organ for genetic therapies (Allocca, Tessitore, Cotugno, & Auricchio, 2006; Auricchio & Rolling, 2005; Bennett & Maguire, 2000) . The partial immune privileged properties of the eye can limit immune responses toward the transgene and the vector. In addition, the eye is enclosed and the presence of the blood-retinal-barrier can help avoiding unintentional spreading of vectors to neighboring tissues as well as to the general circulation.
Retinal diseases are transmitted as monogenic or complex traits. In the last two decades over 130 genes have been identified that cause retinal diseases (Retinal Information Network: www.sph.uth.tmc.edu/Retnet/), and a number of small and large animal models that exist faithfully recapitulate the human pathologies, allowing for the testing of novel treatments.
Inherited retinal degenerations such as retinitis pigmentosa (RP) or Leber Congenital Amaurosis (LCA) (Cremers, van den Hurk, & den Hollander, 2002; Dryja, 2001; Kaplan, Perrault, & Unnich, 2000) are caused by mutations in genes primarily expressed in photoreceptors or the retinal pigment epithelium (RPE). RP and LCA are characterized by extreme genotypic and phenotypic heterogeneity, various patterns of Mendelian inheritance and primary and secondary cell involvement (Dryja, 2001; Kaplan et al., 2000) . Common retinal diseases inherited as complex traits are age-related macular degeneration (AMD), proliferative diabetic retinopathy and retinopathy of prematurity (ROP), which in their severe forms are characterized by ocular neovascularization. The unbalance between pro-and antiangiogenetic molecules in favor of the former is the final common pathogenetic stimulus that triggers the formation of aberrant vessels, eventually leading to blindness in ocular neovascular diseases (Das & McGuire, 2003; Tuo, Bojanowski, & Chan, 2004) . Finally, glaucoma is a common retinal blinding disease characterized by increased intraocular pressure which independently of its monogenic or multifactorial inheritance is associated with retinal ganglion cells apoptosis (Sheffield & Alward, 2000) .
The typical approaches employed to correct retinal diseases caused by recessive or dominant mutations are based on gene replacement or gene inactivation, respectively (Dinculescu, Glushakova, Min, & Hauswirth, 2005; Farrar, Kenna, & Humphries, 2002; Wilson & Wensel, 2003) . In both cases the therapeutic nucleic acids need to be targeted to the cells that are primarily affected by the mutation (i.e. the RPE or photoreceptors). In addition, a generic strategy to delay retinal degeneration or the glaucoma-associated retinal ganglion cell apoptosis has been developed using gene delivery of secretable anti-apoptotic factors or survival factors (Bainbridge, Tan, & Ali, 2006; Borras, Brandt, Nickells, & Ritch, 2002; . Viral-mediated gene delivery of secreted therapeutic proteins has additionally been used to provide symptomatic treatments for those retinal diseases that are characterized by ocular neovascularization. Animal models of AMD and ROP have been successfully treated with AAV vectors encoding for secretable anti-angiogenic molecules Campochiaro, 2007) . The use of soluble molecules in anti-angiogenic and neurotrophic therapy overcomes the problem of specifically targeting affected cells, since the therapeutic protein produced by ''factory cells'' can diffuse across the retina into ocular fluids (Auricchio, 2003) .
Regardless of the retinal disease target and the therapeutic strategy, aspects that are critical to the efficacy of genebased therapies include: (i) route and timing of gene transfer, (ii) efficiency and specificity of retinal cell transduction, and (iii) transcriptional regulation of pattern, time and levels of transgene expression.
Route and timing of gene transfer
The routes of vector administration to the retina determine which cells are exposed to the therapeutic agent. The subretinal approach is typically used for treatment of inherited retinal diseases affecting photoreceptors or RPE. The subretinal administration of AAV vectors results in the transduction of both photoreceptors and RPE cells . AAV vectors have been successfully used to treat small and large animal models with RPE-specific genetic defects including those causing mucopolysaccharidosis VI (Ho et al., 2002) and VII (Hennig et al., 2004) , RP due to a MERTK deficiency , LCA due to an RPE65 gene deficiency (Acland et al., 2005; Acland et al., 2001; Dejneka et al., 2004; Jacobson et al., 2006; LeMeur et al., 2007; Narfstrom et al., 2003; Pang et al., 2006) and Ocular Albinism due to OA1 deficiency (Surace et al., 2005) . Gene transfer approaches for correction of photoreceptor-specific diseases with subretinal injection of AAV vectors were successfully used to recover photoreceptor function in murine models carrying null mutations for the rpgrip (Pawlyk et al., 2005) and rs1h genes Zeng et al., 2004) . Because the subretinal space is near to the choroidal vascular plexus, subretinal administration of AAV vectors encoding for anti-angiogenic factors was also used to treat choroidal neovascularization (Lai et The other route of vector administration is the intravitreal injection, which exposes the inner retina to the therapeutic agent. This route of administration was used to treat optic neuritis in rodents (Guy, Qi, & Hauswirth, 1998; Qi, Hauswirth, & Guy, 2007) , to protect retinal ganglion cells (RGC) in rat models of glaucoma (Martin & Quigley, 2004; McKinnon et al., 2002; Renwick et al., 2006; Zhou, Pernet, Hauswirth, & Di Polo, 2005) and to treat models of retinal neovascularization Bainbridge et al., 2002; Lai et al., 2005; Raisler, Berns, Grant, Beliaev, & Hauswirth, 2002 ).
An additional factor playing a critical role in viral-mediated retinal transduction is the time of gene delivery. Retinal degeneration varies from early and severe to late and progressive. Slowly progressive diseases have a much wider therapeutic window than those with an earlier onset such as LCA2. Timely gene delivery in early onset and congenital retinal dystrophies may prevent the pathological consequences of the mutation to retinal function. Administration of AAVs with reporter or therapeutic genes to the fetal or the newborn murine retina results in robust transgene expression and recovery of retinal pathology in both models of retinal degeneration and neovascularization Bainbridge et al., 2002; Dejneka et al., 2004; Lai et al., 2005; Raisler et al., 2002; .
Efficiency and specificity of retinal cell transduction
To be effective, gene therapy to the retina initially requires efficient, specific and widely distributed transduction of virus to target cells. Once this is achieved, it is possible to tailor gene expression to appropriate levels and spatial patterns through the use of specific promoter elements. Therefore, the main limiting step in the process is the targeted transduction mediated by AAV. This includes: vector binding to a specific receptor and entry into the target cell; intracellular trafficking to the nucleus; AAV decapsidation and conversion of its single-strand genome into a DNA duplex; transgene expression . The first AAV serotype tested into the retina was AAV2/2 (Ali et al., 1996) . The subretinal administration of this serotype results in the transduction of both photoreceptors and RPE cells, with an onset of transgene expression that peaks at 4 weeks after vector administration (Ali et al., 1996; Auricchio et al., 2001; Bennett, Duan, Engelhardt, & Maguire, 1997; Flannery et al., 1997; Rabinowitz & Samulski, 2002; Rolling et al., 2000; Rolling et al., 1999; Sarra et al., 2002) . Intravitreal administration of AAV2/2 results in transduction of ganglion cells, trabecular meshwork cells and various cells of the inner nuclear layer, including Mü ller cells (Ali et al., 1998; Auricchio et al., 2001; Borras et al., 2006; Liang et al., 2001; Martin, Klein, & Quigley, 2002) . The availability of AAV vectors derived from different serotypes has enormously enhanced AAV transduction efficiency and specificity ( Interestingly, following subretinal delivery of AAV2/1, 2/6 or 2/4 vectors, robust expression of the EGFP reporter gene is observed in the RPE of mice, dogs and non-human primates (NHP) Weber et al., 2003; Yang et al., 2002) . Subretinal administration of AAV5/5 (where both genome and capsids belong to AAV5) or AAV2/5 also results in early RPE transduction, but more importantly, in robust expression in photoreceptors which is higher than that obtained with AAV2/2. Lotery et al., 2003; Yang et al., 2002) (Fig. 2) . Notably, intravitreal injection of AAV2/1 and 2/5 resulted in poor transduction of the inner retina ). More recently large numbers of novel AAV capsid sequences have been isolated (see above) and some of these were used for the generation of novel AAV vectors, potentially allowing for further expansion of AAV retinal tropism and transduction (Fig. 1) . Based on the ability of AAV2/7, 2/8, and 2/9 to transduce various tissues (Cearley & Wolfe, 2006; Gao et al., 2002; Inagaki et al., 2006; Pacak et al., 2006) , we recently tested their transduction characteristics in the murine retina. Subretinal delivery of AAV2/7 (Fig. 2) , 2/8, or 2/9 (data not shown) vectors encoding EGFP, resulted in efficient transduction of both RPE and photoreceptor cells. The ability of AAV2/7 and 2/8, as well as of AAV2/5 (to date considered the best vector for photoreceptor transduction) to efficiently and rapidly transduce murine photoreceptors may have a significant impact on developing therapies for severe inherited photoreceptor diseases. To this end, gene replacement with AAV2/2 vectors in the rdl and rds murine models (due to deficiency in the pde6b and peripherin genes, respectively) resulted in low levels of photoreceptor transduction and in lack of rescue or in short-lived rescue (Ali et al., 2000; Jomary, Vincent, Grist, Neal, & Jones, 1997; Sarra et al., 2001; Schlichtenbrede et al., 2003) .
Transcriptional regulation of pattern, time and levels of transgene expression
In inherited retinal diseases, stable expression of the therapeutic gene is required at appropriate levels and should be restricted to the cells in which the mutation exerts its detrimental effect. Conversely, in diseases such as retinal neovascularization, both levels and timing of transgene expression should be regulated. Tissue-specific promoters for RPE restricted gene expression include promoter fragments from the RPE65, VMD2, and OA1 genes (Acland et al., 2005; Dinculescu et al., 2005; Vetrini et al., 2004) . The proximal promoter region of the rod opsin gene (RPPR) is used for photoreceptor-specific expression (Flannery et al., 1997; Glushakova et al., 2006) . As shown in Fig. 2 , subretinal administration of an AAV2/5 encoding EGFP under the control of the ubiquitous CMV promoter results in expression in both RPE and photoreceptor cells, while the same AAV serotype harboring the RPPR promoter restricts EGFP expression to photoreceptors.
Systems to regulate the timing and levels of gene expression have been developed to obtain therapeutic efficacy and avoid toxicity. For this purpose transcription factors have been engineered that are regulated either positively or negatively by small molecule drags (Clackson, 2000) . Two inducible systems have been tested in the murine and NHP retina transduced with AAV vectors. One is based on the ability of rapamycin to reconstitute a functional transcription factor that binds to a promoter element upstream of the target gene (Pollock et al., 2000; Rivera et al., 1996) . Subretinal administration of AAV containing the regulated system followed by systemic administration of rapamycin result in expression of the target gene that is drug-dependent in time and levels (Auricchio, Rivera, et al., 2002; Lebherz et al., 2005) . Similar results have been obtained using the tetracycline (tet)-inducibile system, in which an activator or silencer (tetON or tetOFF, respectively) vector and an inducible doxycycline (dox)-responsive vector were subretinally injected in rats and NHP Folliot et al., 2003; McGee Sanftner, Rendahl, & Quiroz, 2001; Smith et al., 2005; Stieger et al., 2006) .
In conclusion, the versatility, efficacy and safety of AAV vectors for retinal gene transfer have been successfully determinate in animal models. AAV safety and efficacy is being tested in patients with LCA2 due to RPE65 mutations (http://www.blindness.org; Bennett, 2006) . This may allow to treat many additional retinal diseases. 
